Play all audios:
An updated version of Exact Sciences’ stool-based colorectal cancer screening test detected cancer accurately in a massive study, triggering fewer false alarms than its current product, the
company announced Tuesday. While the biotech plans to use the data to apply for regulatory approval, cancer specialists say they’ll need to see more details before concluding the new test is
a real and meaningful improvement over the current one. The results come from a 20,000-person study of a new version of the company’s Cologuard test, which detects molecular markers of
cancer in patients’ feces. Participants in the trial, dubbed Blue-C, received either the updated Cologuard test or a so-called fecal immunochemical test, or FIT, which detects blood in
stool. The new Cologuard test correctly detected cancer 94% of the time, and it correctly returned a negative result 91% of the time, test characteristics known as sensitivity and
specificity, respectively. A 2013 trial of the first iteration of Cologuard, known as DeeP-C, showed the test is 92% sensitive and 87% specific. Put differently, Cologuard returned false
positive results 13% of the time in the earlier study among people who don’t have cancerous cells or cells that show early signs of transforming into cancer, compared to a 9% false positive
rate with this next version of the test. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND
ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+.
Subscribe